Introduction {#S1}
============

Carbapenems are considered as last-resort antibiotics useful for the treatment of infectious diseases caused by multidrug-resistant (MDR) Gram-negative microorganisms; however, the recent increase of carbapenemase-producing *Enterobacteriaceae* (CPE) has limited their therapeutic use in public health ([@B16]). NDM is one of the most clinically significant carbapenemases, exhibiting a broad spectrum of activity to all penicillins, cephalosporins, and carbapenems, except aztreonam ([@B18]). Since the first report of NDM-1 in 2008, 24 NDM variants have been identified and disseminated worldwide at different extent ([@B42]). In 2011 NDM-5, which has two amino substitutions (Val88Leu and Met154Leu) compared to NDM-1 ([@B44]), was reported for the first time in clinical *Escherichia coli* strain isolated in the United Kingdom ([@B17]). Not long after, it has been reported in Japan ([@B26]), China ([@B38]), United States ([@B24]), South Korea ([@B29]), Lebanon ([@B12]). In Italy, NDM-5 was firstly reported in 2017 from an *E. coli* strain isolated from a patient with travel history to Thailand, who was hospitalized in Desenzano del Garda ([@B6]). According to ECDC 2018--2019 regional report^[1](#footnote1){ref-type="fn"}^, outbreaks with involvement of NDM-producers have been increasingly reported from Italy.

OXA-48-like types hydrolyze penicillins at a high level and carbapenems at lower level spearing broad-spectrum cephalosporins and are not inhibited by clavulanic acid, tazobactam, and sulbactam ([@B34]). Since the first identification in 2001 in Turkey ([@B33]), 11 *bla*~OXA--48~ gene variants have been reported. Among those, OXA-181 has globally led to a fast spread, causing infections mainly in patients with travel history to the Indian subcontinent ([@B10], [@B23]). The *bla*~OXA--181~ gene has been detected mostly in *Klebsiella pneumoniae*, with some reports on NDM-5 and OXA-181 co-production in hospitalized patient in South Korea ([@B11]) and in a patient hospitalized in India then in the United States ([@B35]). As suggested in many studies, horizontal transfer of OXA-48-like plasmids between *K. pneumoniae* and commensal *E. coli* can occur in patients initially colonized by hyper-epidemic clones of *K. pneumoniae* ([@B28]).

Co-production of NDM and OXA-48-like in *E. coli* was reported in Italy ([@B25]), South Korea ([@B2]), Myanmar ([@B1]), and Iran ([@B39]). The recent dissemination of NDM- and OXA-48-like -producing *E. coli* is usually not related to a single clone but involving multiple sequence types (STs) such as ST410 and ST10 (Pasteur scheme). This sporadic but global dissemination is leading *E. coli* to serve as potential secondary reservoir of such class B and D carbapenemases ([@B27]). Moreover, international travels and migration flows greatly contribute to global spread of carbapenemase producing bacteria.

The aim of this study was to genetically characterize two carbapenemase-producing *E. coli* strains with OXA-181 and/or NDM-5 enzymes and collected form a baby affected by diarrhea; this is a second report from Desenzano del Garda (Brescia, Northern Italy) hospital, where the *bla*~NDM--5~ was detected for the first time in Italy (in an *E. coli* strain), in 2015.

Materials and Methods {#S2}
=====================

Bacterial Isolation {#S2.SS1}
-------------------

In September 26, 2018, at the Clinical Microbiology Laboratory of Manerbio Hospital (Desenzano, Brescia, Italy) two *E. coli* strains were obtained from a stool specimen of a baby (age between 1 and 5 years old) of Indian origin. The outpatient was suffering from diarrhea and had a travel history to India before being hospitalized in Italy. A Film array gastrointestinal panel (BioFire FilmArray GI Panel, BioMerieux, France) was performed for the evaluation of diarrheagenic *E. coli*, that resulted positive for enteropathogenic *E. coli*. Antibiotic treatment was not initiated. However, patient was treated symptomatically due to diarrhea and discharged after 1 week (October 06, 2018). The two *E. coli* strains (5M and 5P) were carbapenem-resistant and resulted positive for NDM-like for 5P and NDM-like and OXA-48-like production for 5M by Xpert Carba-R test (GeneXpert, Cepheid). Then the isolates were sent to the University of Pavia, where carbapenemase production was confirmed by the KPC/MBL Confirm kit (Rosco Diagnostic) and polymerase chain reaction (PCR) ([@B3]; [@B6]). Finally, the isolates were sent to Charles University in Prague for further genomic characterization.

Carbapenemase Production Confirmation and Susceptibility Testing {#S2.SS2}
----------------------------------------------------------------

The strain species identification was confirmed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using MALDI Biotyper software (Bruker Daltonics, Bremen, Germany). Carbapenemase production was tested by MALDI-TOF MS meropenem hydrolysis assay ([@B36]). Production of different carbapenemases (metallo-beta-lactamase, OXA-48 and KPC) was tested using double-disc synergy test with EDTA, phenylboronic acid test and temocillin disc test ([@B22]; [@B14]; [@B15]), respectively. Antimicrobial susceptibility was performed by AutoScan4 System (Beckman Coulter), tigecycline was evaluated using broth microdilution according to EUCAST guidelines^[2](#footnote2){ref-type="fn"}^.

Plasmid Conjugation {#S2.SS3}
-------------------

Conjugal transfer of resistance determinants was tested in liquid medium using the *E. coli* A15 strain (Rif^*r*^) as recipient. Transconjugants were selected on Mueller-Hinton agar plates containing rifampicin (100 mg/l) and ampicillin (50 mg/l). The presence of *bla*~CMY--like~, *bla*~NDM--like~, and *bla*~OXA48--like~ in the respective transconjugants were confirmed by PCR.

Plasmid Size {#S2.SS4}
------------

Plasmid size that carried *bla*~NDM--like~ genes was detected by pulsed-field gel electrophoresis (PFGE) of total DNA digested with S1 nuclease (Promega, Madison, WI, United States; [@B4]). Then the DNA was transferred to a BrightStar-Plus positively charged nylon membrane (Applied Biosystems, Foster City, CA, United States) and hybridized with digoxigenin- labeled *bla*~NDM--like~ probe ([@B30]).

Whole-Genome Sequencing and Annotation {#S2.SS5}
--------------------------------------

The genomic DNA of the two *E. coli* strains was extracted using NucleoSpin Microbial DNA kit (Macherey-Nagel, Germany). Sequel I platform (Pacific Biosciences, Menlo Park, CA, United States) was used for sequencing. Library preparation was done following the microbial multiplexing protocol according to the manufacture instructions for sheared DNA. Shearing was performed using g-tubes (Covaris, United States), and no size selection was done during the library preparations. HGAP4 was used to perform the assemblies of the genomes with minimum seed coverage of 30. ResFinder 3.2^[3](#footnote3){ref-type="fn"}^ ([@B45]), PlasmidFinder^[4](#footnote4){ref-type="fn"}^ ([@B9]), VirulenceFinder 2.0^[5](#footnote5){ref-type="fn"}^ ([@B19]) ISfinder database^[6](#footnote6){ref-type="fn"}^, MLST 2.0^[7](#footnote7){ref-type="fn"}^ ([@B21]), and CHTyper 1.0^[8](#footnote8){ref-type="fn"}^ ([@B8]) were utilized to detect resistance genes, plasmid replicon type, virulence genes, mobile elements, multilocus sequence types (STs) (according to Oxford and Pasteur schemes) and FimH/FumC type respectively. Open reading frame (ORF) were predicted using RAST 2.0 ([@B7]) with default parameters combined with BLASTP/BLASTN. Comparative genome alignments were performed using the Mauve (version 2.3.1). Gene organization and diagrams were sketched using Inkscape 0.92.4^[9](#footnote9){ref-type="fn"}^.

Nucleotide Sequence Accession Numbers {#S2.SS6}
-------------------------------------

The nucleotide sequences of pISV_IncI_CMY-42, pISV_IncFII_NDM-5, and pVSI_IncFII_NDM-5 plasmids were deposited in the GenBank under the accession numbers [MN242251](MN242251), [MN218686](MN218686), and [MN197360](MN197360), respectively.

Results {#S3}
=======

The *E. coli* 5M and 5P strains exhibited clinical resistance to piperacillin, piperacillin-tazobactam, cefotaxime, ceftazidime, aztreonam, meropenem, ertapenem, gentamicin, tetracycline, trimethoprim-sulfamethoxazole, ciprofloxacin, amikacin and chloramphenicol, while remained susceptible to tigecycline and colistin \[breakpoints (see text footnote 2)\]. Whereas 5P was found to carry a *bla*~NDM--5~ gene, 5M carried both *bla*~NDM--5~ and *bla*~OXA--181~.

The β-lactamase genes were transferable through conjugation in both clinical isolates. The isolate 5P transferred one plasmid (pVSI_NDM-5) to the recipient successfully, while 5M transferred the three plasmids (pISV_InvFII_NDM-5, pISV_IncX3_OXA181, and pISV_IncI_CMY-42) to the recipient ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

Whole-genome sequencing revealed that 5P belonged to the sequence type ST405/ST477 (according to Pasteur/Oxford schemes), serotype O102:H6 and the CH-Type FumC37/FimH27 (fimbrial adhesion gene f*imH* with allele 27 and fumarate hydratase class II gene *fumC* with allele 37). Moreover, it carried virulence genes encoding *air*, *gad*, *iha* and *sat* coding for enteroaggregative immunoglobulin repeat protein, glutamate decarboxylase, adherence protein and secreted autotransporter toxin respectively. The isolate 5P carried a 130562 bp multi-replicon plasmid IncFII/IncFIA/IncFIB (pVSI_NDM-5). pVSI_NDM-5 plasmid backbone exhibited high similarity scores with the 1336947 bp plasmid pM309-NDM5 carried by an *E. coli* strain isolated in Myanmar in 2019 (AP018833.1; [@B40]) (99.94% sequence identity, 82% query coverage). pVSI_NDM-5 backbone carried regions responsible for replication (*repA*, *repB*, *repE*), conjugative transfer system (*tra*, *finO* genes), maintenance and stability (*parA*, *parB*), toxin-antitoxin (TA) systems (*vapC/vapB*, *ccdA/ccdB*, *pemI/pemK*). Moreover, pVSI_NDM-5 carried two main antibiotic resistance islands (ARI-I and ARI-II); ARI-I, 10030 bp in size, carried genes coding for β-lactam resistance (*bla*~OXA--1~, *bla*~CTX--M--15~), fluoroquinolone and aminoglycoside resistance (*aac(6′)-lb-cr*) and phenicol resistance (*catB3*). ARI-I resembled high similarity scores with plasmids from *K. pneumoniae* and *E. coli* (100% sequence similarity and coverage; United States CP023950.1, Denmark MG462728.1) and chromosomal sequences in *Enterobacter cloacae* from Thailand (CP040827.1). While ARI-II, 15326 bp in size, carried genes coding for sulfonamide resistance (*sul1*), β-lactam resistance (*bla*~NDM--5~, *bla*~TEM--1B~), phenicol resistance (*catB3*), trimethoprim resistance (*dfrA17*), antiseptic resistance (*qacE*Δ*1*) and aminoglycoside resistance (*aadA5*, *rmtB*). ARI-II was a composite transposon consisting of two structures: the first structure harbored the *bla*~NDM--5~ gene with two IS*26* in the same direction on the flanks and another structure harbored *cdu2*, *rmtB* and *bla*~TEM--1B~ mediated by another IS*26* on one end in the same direction ([Figure 1](#F1){ref-type="fig"}).

![Linear map of pIBA_IncFII_NDM5, pVSI_IncFII_NDM-5, and pISV_IncFII_NDM-5; Arrows show the direction of transcription of ORFs while rectangles show truncated ORFs. Replicons, partitioning genes, mobile elements, conjugal transfer genes, antibiotic resistance, *bla*~NDM--5~, other remaining genes and stability genes are designated by violet, gray, yellow, green, red, pink white, and orange, respectively. Gray shaded area shows the nucleotide similarity between the three plasmids. Different Antibiotic resistance islands (ARI) are marked by a horizontal black line.](fmicb-10-03095-g001){#F1}

The isolate 5M belonged to the sequence type ST2659/ST759 serotype O50/02:H18 and the CH-Type FumC26/FimH5 (fimbrial adhesion gene f*imH* with allele 5 and fumarate hydratase class II gene *fumC* with allele 26). Moreover, it carried virulence genes encoding *air*, *gad*, *astA*, *capU* and *eilA* coding for enteroaggregative immunoglobulin repeat protein, glutamate decarboxylase, heat-stable toxin, hexosyltransferase protein and salmonella HilA homologous protein respectively. The isolate 5M carried four plasmids: a 153866 bp multi-replicon plasmid IncFII/IncFIA/IncFIB pISV_IncFII_NDM-5 ([Figure 1](#F1){ref-type="fig"}), a 41143 bp IncI plasmid pISV_IncI_CMY-42 ([Figure 2](#F2){ref-type="fig"}), a 51480 bp IncX3 plasmid (pISV_IncX3_OXA181) ([Figure 3](#F3){ref-type="fig"}) and an 89866 bp IncI1 plasmid (no resistance genes detected). pISV_IncFII_NDM-5 plasmid backbone carried regions responsible for replication (*repA*, *repB*, *repE*), conjugative transfer system (*tra*, *trb*, *finO* genes), maintenance and stability (*parA*, *parB*, *stb*), TA systems (*ccdA/ccdB*, *pemI/pemK*, *doc*). Moreover, pISV_IncFII_NDM-5 carried two main antibiotic resistant islands (ARI-III and ARI-IV); ARI-III, 12220 bp in size, carried genes coding for β-lactam resistance (*bla*~OXA--1~), fluoroquinolone and aminoglycoside resistance (*aac(6′)-lb-cr*), tetracycline resistance (*tet(B)*) and phenicol resistance (*catB3*, *catA1*). ARI-IV, 26527 bp in size, carried genes coding for macrolide resistance (*erm(B)*, *mph(A)*), sulfonamide resistance (*sul1*), β-lactam resistance (*bla*~NDM--5~, *bla*~TEM--1B~), trimethoprim resistance (*dfrA14*, *dfrA12*), antiseptic resistance (*qacE*Δ*1*) and aminoglycoside resistance (*aadA5*). ARI-IV was found to be in a plasmid isolated in 2017 from an *E. coli* strain in Myanmar pM217_FII (100% sequence similarity, 92% query coverage; AP018147.1) ([@B41]).

![Circular map of pISV_IncI_CMY-42 plasmid compared to pIBAC_IncI_CMY-42 (inner most gray circular box); green arrows represent conjugal transfer system of the plasmid, red arrows represent antibiotic resistance genes, yellow arrows/boxes represent complete/truncated mobile elements, white arrows represent hypothetical proteins, purple arrow represents the replication protein rep_IncI. Further more, the red-arced box represents the plasmid Antibiotic Resistance Island (ARI).](fmicb-10-03095-g002){#F2}

![Circular map of pISV_IncX3_OXA181 plasmid; green arrows represent conjugal transfer system of the plasmid, red arrow represents the *qnrS1* gene, blue arrow represents the *bla*~OXA--181~ gene, yellow arrows/boxes represent complete/truncated mobile elements, white arrows/boxes represent complete/truncated hypothetical proteins, purple arrows/boxes represent complete/truncated replication protein. Further more, the black inner-curved box represents the plasmid backbone while the red one represents the plasmid Antibiotic Resistance Island (ARI).](fmicb-10-03095-g003){#F3}

The sequence comparison of the two NDM-5 producing plasmids (isolated from 5M and 5P) along with the first reported plasmid producing NDM-5 in Italy revealed that the backbones, and the ARIs, are in some way different. In fact, even though *E. coli* 5P belongs to the same ST405 of the first Italian NDM-5 producing *E. coli* strain (ECDT-2_GA) previously collected from the same hospital and the plasmid belongs to the incompatibility group IncFII (same as the plasmid pIBAC_IncFII_NDM5), the plasmid backbone (*rep*, *tra* and stability genes) were different as well as TA systems ([@B6]).

pVSI_IncFII_NDM-5 (carried by 5P) shared most of the regions found in pIBAC_IncFII_NDM5 with more acquired regions as shown in [Figure 1](#F1){ref-type="fig"}. Both of the plasmids shared the ARI-II (in opposite direction); even though pIBAC_IncFII_NDM5 had another segment harboring *erm(B)* and *mph(A)* with 2 IS*25* flanking the peripheries in opposite direction, adjacent to the segment resembling ARI-II. Interestingly, pVSI_IncFII_NDM-5 and pISV_IncFII_NDM-5 shared some regions of the backbone but not with pIBAC_IncFII_NDM5. The ARIs of the two plasmids shared some regions, however pISV_IncFII_NDM-5 ARI-III/IV were larger and carried more resistance genes than pVSI_IncFII_NDM-5 ARI-I/II (except for *bla*~CTX--M--15~ and *bla*~TEM--1B~ found in pVSI_IncFII_NDM-5 only). The re-arrangement of the plasmid backbone in both pISV_IncFII_NDM-5 and pVSI_IncFII_NDM-5), and the excessive presence of insertion sequences (especially IS*26*) in ARIs lead to the formation of complex transposons with similar insertion sequences on the flanking regions (such as in ARI-IV and ARI-II) suggest the possibility of transfer of such regions. Nevertheless, this also suggest that the plasmid itself is not conserved.

pISV_IncI_CMY-42, that harbored the *bla*~CMY--42~ gene coding for beta-lactam resistance, exhibited high similarity to plasmid pCMY-42 (KY463221.1; 99.48% sequence similarity 93% query coverage) isolated in 2017 from an *E. coli* strain in Italy ([@B6]). While pISV_IncX3_OXA181, which harbored genes coding for quinolone resistance (*qnrS1*) and beta-lactam resistance (*bla*~OXA--181~), showed 100% sequence similarity and coverage to several plasmids found in NCBI database (AP018837.1 ([@B40]); Myanmar, MG893567.1; China, CP024806; Denmark, MG570092; Lebanon ([@B5]), KX894452.1; Germany, KX523903; Czechia).

Discussion {#S4}
==========

Here we report a patient with diarrhea that carried two different *E. coli* strains (ST405/ST477 and ST2659/ST759) from the same patient. *E. coli* strain 5P carries one multi-replicon plasmid harboring *bla*~NDM--5~. The strains were detected by BioFire FilmArray GI panel (BioMerieux), which is based on a multiplex PCR system with a total runtime of about an hour. This method simultaneously tests for 22 targets including Diarrheagenic *E. coli/Shigella*. While the other *E. coli* strain 5M carries three plasmids harboring resistance genes; the first plasmid is a multi-replicon plasmid harboring *bla*~NDM--5~, the second plasmid harbors *bla*~OXA--181~ and the third plasmid harbors *bla*~CMY--42~. *E. coli* (ST405/ST477) has been reported as an emerging extraintestinal pathogenic *E. coli* (ExPEC), however it is still unknown whether it is a globally dispersed emerging clone, or the disease caused is due to sporadic episodes caused by genetically divergent ST405 isolates ([@B13]). Furthermore, *E. coli* (ST2659/ST759) has been described so far in two reports from Algeria as a cause of clinical infection ([@B37]; [@B43]). We hypothesize that the *E. coli* strain (ST2659/ST759) is causing the diarrhea in our patient due to the production of the heat stable toxin (*astA*) which was reported elsewhere as being the cause of diarrhea in patients ([@B20]).

The plasmids pVSI_IncFII_NDM-5 and pISV_IncFII\_ NDM-5 shared relatively little of its genetic content ([Figure 1](#F1){ref-type="fig"}). The backbones shared: two segments carrying the replicons and partitioning related genes and another segment harboring the ABC transporter system. Moreover, pVSI_IncFII_NDM-5 shared all of its conjugative transfer system (*tra* genes). Nevertheless, pVSI_IncFII_NDM-5 had more *tra* genes and the genes were found in a consecutive manner (complete without interruption) which is not the case in pVSI_IncFII_NDM-5. Moreover, both of ARI-III and ARI-IV of pISV_IncFII_NDM-5 were bigger in size than ARI-I and ARI-II of pVSI_IncFII_NDM-5. Apart of ARI-I being partially present in ARI-III, a part of ARI-II was also present in ARI-IV. The fact that all the ARIs in both plasmids are composite transposons strongly suggests that acquiring/losing segments of ARIs is possible as shown here ([Figure 1](#F1){ref-type="fig"}). Moreover, the position of ARI-II within the conjugal transfer system while ARI-IV (which contain part of the ARI-II) is located after the conjugal transfer system suggests some rearrangements within the plasmid structure.

On the other hand, the comparison of pISV_IncI\_ CMY-42 with the plasmid pIBAC_IncI_CMY-42 isolated with pIBAC_IncFII_NDM-5 ([@B6]), showed similar plasmid structure except for a small segment that harbored *parM*, *parB*, *stbB* and SOS protein, which was replaced by a segment harboring some hypothetical proteins with the insertion sequence IS*Cro* ([Figure 2](#F2){ref-type="fig"}). pISV_IncX3_OXA181 was the most conserved plasmid among reported IncX3 plasmids harboring the *bla*~OXA--181~. This successful plasmid that has been reported elsewhere has conserved plasmid backbone as well as conserved ARI ([@B31]). This hypothesis is supported by the fact that there is an increasing incidence of this plasmid (100% sequence similarity and query when blasted against the NCBI database) in different geographic settings and this confirms the ease of dissemination of this plasmid ([@B5]; [@B40]).

Conclusion {#S5}
==========

In conclusion, the detection of two clinically important MDR *E. coli* clones (the pandemic ST405/477 and the toxigenic ST2659/ST759) from the same patient, represents an unusual and concerning picture, despite the increase of NDM outbreaks reports are in Italian area. The presence of genetically different plasmids harboring *bla*~NDM--5~, suggests that traveling from the Far East countries strongly contributes to the spread of NDM-type class B carbapenemases and suggests the possibility of the presence of hidden reservoirs/healthy carriers in Italy ([@B32]; [@B6]). The high genomic rearrangement-taking place in these plasmids structure (NDM encoding IncF plasmids) could be explained by the diverse exerted selective pressure in different geographical areas and settings. Finally, the presence of two plasmids harboring *bla*~OXA--181~ and *bla*~NDM--5~, respectively in the same ST2659/ST759 *E. coli* strain confirms the increasing trend in co-replicon existence, which limits the therapeutic options and increase the dissemination risk.
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